Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Clinical trial NCT05407584 · UNKNOWN

Trial details

NCT number: NCT05407584
Sponsor: Yonsei University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Start date: 2022-07-05
Primary completion: 2024-05-01
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.